David J. Vaughn

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone

James D. Lewis, Assiamira Ferrara, Tiffany Peng et al. · Diabetes Care · 2011 · 621 citations · Full text

Medicine, Oncology, Pharmacology +13

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Yves Fradet, Joaquim Bellmunt, David J. Vaughn et al. · Annals of Oncology · 2019 · 488 citations · Full text

Medicine, Oncology, Pharmacology +14

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

Joaquim Bellmunt, Toni K. Choueiri, Ronan Fougeray et al. · Journal of Clinical Oncology · 2010 · 454 citations

Medicine, Oncology, Chemotherapy +11

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy D. Gilligan, Daniel W. Lin, Rahul Aggarwal et al. · Journal of the National Comprehensive Cancer Network · 2019 · 451 citations

Medicine, Oncology, Surgery +16